- 21-Dec-2012 Novartis drug Exjade® approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia »
- 15-Dec-2012 Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder »
- 11-Dec-2012 Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis disease burden and suggest overall survival advantage »
- 10-Dec-2012 Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec® »
- 04-Dec-2012 Novartis Foundation symposium discusses psychosocial support to help vulnerable children achieve mental health and wellbeing for a better future in sub-Saharan Africa »
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.